Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Molecular bilayer structure
Patent
1977-02-18
1979-03-27
Padgett, Benjamin R.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Molecular bilayer structure
260112R, 424 85, 424 88, 424 12, G01N 3316, A61K 4300
Patent
active
041466039
ABSTRACT:
A new class of glycoproteins has been found to be produced by human cancer cells and is not produced by normal cells and said glycoprotein is present in the sera of cancer patients. This tumor specific glycoprotein can be characterized by its isoelectric point of from about 4.2 to 4.6 and by the perchloric acid soluble fraction thereof having a sialic acid content of above about 0.065 mg/ml of initial serum sample. The presence of a tumorigenic cancer in a patient can be determined by detecting the presence of the tumor specific glycoprotein in the blood sera of a patient.
REFERENCES:
patent: 4010251 (1977-03-01), Green
Burger et al., Chemical Abstracts, vol. 72, No. 5, Feb. 2, 1970, p. 153.
Duesberg et al., Chemical Abstracts, vol. 73, No. 17, Oct. 26, 1970, p. 95.
Miroff et al., Nature, vol. 227, No. 5364, Sep. 19, 1970, pp. 1243-1244.
Makita et al., Biochimica et Biophysica Acta, vol. 241, No. 2, Aug. 13, 1971, pp. 403-411.
Bolmer Sally D.
Davidson Eugene A.
Nucker Christine M.
Padgett Benjamin R.
Research Corporation
Rosen Gerald S.
Sanders, Jr. Robert J.
LandOfFree
Tumor specific glycoproteins and method for detecting tumorigeni does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor specific glycoproteins and method for detecting tumorigeni, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor specific glycoproteins and method for detecting tumorigeni will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1821812